Onconetix (ONCO) Competitors $1.08 -0.06 (-5.26%) (As of 05:46 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ONCO vs. BRNS, LEXX, ELEV, CLNN, ESLA, PMN, ICCC, LTRN, ACST, and PASGShould you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Barinthus Biotherapeutics (BRNS), Lexaria Bioscience (LEXX), Elevation Oncology (ELEV), Clene (CLNN), Estrella Immunopharma (ESLA), ProMIS Neurosciences (PMN), ImmuCell (ICCC), Lantern Pharma (LTRN), Acasti Pharma (ACST), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Onconetix vs. Barinthus Biotherapeutics Lexaria Bioscience Elevation Oncology Clene Estrella Immunopharma ProMIS Neurosciences ImmuCell Lantern Pharma Acasti Pharma Passage Bio Onconetix (NASDAQ:ONCO) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability. Do institutionals and insiders believe in ONCO or BRNS? 23.9% of Onconetix shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 11.4% of Onconetix shares are held by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend ONCO or BRNS? Barinthus Biotherapeutics has a consensus target price of $5.83, suggesting a potential upside of 548.87%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Onconetix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ONCO or BRNS? Onconetix has a beta of 3.72, meaning that its stock price is 272% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Does the media refer more to ONCO or BRNS? In the previous week, Barinthus Biotherapeutics had 7 more articles in the media than Onconetix. MarketBeat recorded 7 mentions for Barinthus Biotherapeutics and 0 mentions for Onconetix. Barinthus Biotherapeutics' average media sentiment score of 0.29 beat Onconetix's score of 0.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Onconetix Neutral Barinthus Biotherapeutics Neutral Which has preferable earnings and valuation, ONCO or BRNS? Onconetix has higher earnings, but lower revenue than Barinthus Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnconetix$60K149.22-$37.41MN/AN/ABarinthus Biotherapeutics$14.97M2.37-$73.35M-$1.49-0.60 Is ONCO or BRNS more profitable? Barinthus Biotherapeutics' return on equity of -34.26% beat Onconetix's return on equity.Company Net Margins Return on Equity Return on Assets OnconetixN/A -1,472.15% -57.57% Barinthus Biotherapeutics N/A -34.26%-29.30% Does the MarketBeat Community believe in ONCO or BRNS? Barinthus Biotherapeutics received 14 more outperform votes than Onconetix when rated by MarketBeat users. CompanyUnderperformOutperformOnconetixN/AN/ABarinthus BiotherapeuticsOutperform Votes14100.00% Underperform VotesNo Votes SummaryBarinthus Biotherapeutics beats Onconetix on 10 of the 14 factors compared between the two stocks. Ad Crypto 101 Media“Sleeping Giant” Crypto Set to Explode…What if I told you there's a crypto that could make Bitcoin look like small change? We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Get Onconetix News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCO vs. The Competition Export to ExcelMetricOnconetixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.87M$6.37B$4.98B$8.81BDividend YieldN/A8.11%5.18%4.07%P/E RatioN/A10.05131.9617.55Price / Sales164.42326.621,218.6491.35Price / CashN/A22.1633.2632.46Price / Book0.405.414.644.65Net Income-$37.41M$153.11M$118.24M$225.37M7 Day Performance-31.61%-4.23%-2.45%-2.13%1 Month Performance-79.66%-8.68%-4.02%-0.20%1 Year PerformanceN/A27.82%29.47%24.42% Onconetix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOOnconetix0.2184 of 5 stars$1.08-5.3%N/AN/A$8.95M$60,000.000.0012Gap UpBRNSBarinthus Biotherapeutics2.2449 of 5 stars$0.90+1.2%$5.83+548.9%-67.7%$35.55M$14.97M-0.60107Analyst ForecastGap UpLEXXLexaria Bioscience1.955 of 5 stars$2.20+1.4%$11.00+400.0%+65.7%$34.80M$411,019.00-4.937News CoverageELEVElevation Oncology2.0194 of 5 stars$0.58+0.2%$7.80+1,242.3%+16.0%$34.35MN/A-0.7140CLNNClene3.197 of 5 stars$4.09-12.2%$71.33+1,644.1%-48.7%$34.19M$421,000.00-0.76100Analyst RevisionNews CoverageESLAEstrella Immunopharma0.6899 of 5 stars$0.92+8.2%N/A-31.9%$33.30MN/A-3.27N/ANews CoveragePMNProMIS Neurosciences0.9543 of 5 stars$1.00+0.7%N/A-26.7%$32.60M$10,000.00-9.906Gap DownICCCImmuCell0.5813 of 5 stars$3.60flatN/A-24.4%$32.08M$17.47M-7.2875News CoverageGap DownLTRNLantern Pharma1.5615 of 5 stars$2.94-4.5%N/A-23.6%$31.71MN/A-1.7320Positive NewsGap DownACSTAcasti Pharma2.4044 of 5 stars$3.37-0.9%$10.00+196.7%+55.3%$31.68MN/A-2.3432News CoveragePASGPassage Bio2.9707 of 5 stars$0.51+5.8%$9.00+1,664.7%-19.7%$31.50MN/A-0.41130 Related Companies and Tools Related Companies BRNS Alternatives LEXX Alternatives ELEV Alternatives CLNN Alternatives ESLA Alternatives PMN Alternatives ICCC Alternatives LTRN Alternatives ACST Alternatives PASG Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONCO) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | SponsoredThe Stock Powering Musk’s AI Revolution—RevealedImagine being able to invest in Tesla, PayPal, or SpaceX before the world knew their potential. Today, you ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
